With this background in mind, Cosmi and colleagues assessed in four randomized controlled trials (RCTs) and in a real-world survey whether insulin treatment was associated with an increased risk of hospitalization for HF. 5 Given that patients receiving insulin are usually older, co-morbid, and with longer duration of the disease than those who are not on insulin, the authors used propensity score matching algorithm to minimize confounding. Although of value, there are several problems in their study. The analysis of the four RCTs is of limited value because it compensates for endpoints that were not pre-specified when the studies were designed. Furthermore, in the real-world survey, they matched for several covariates known to drive physicians to prescribe insulin, such as co-morbidities, liver disease, cancer, and diabetes duration, but they did not consider or could not collect data on other key variables known to influence the beginning of insulin treatment, such as the historical sequence of glucose-lowering medications, the overall exposure to glycated haemoglobin (HbA 1c ) levels, body mass index, and glomerular filtration rate. RCTs specifically designed to assess whether exogenous insulin is safe or not, are available. The Outcome Reduction with an Initial Glargine Intervention (ORI-GIN) trial showed that glargine was not associated with higher risk of hospitalization for HF (hazard ratio 0.90, 95% confidence interval 0.77-1.05); 6 the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) demonstrated that the rate of new-onset HF did not differ significantly between patients in the insulin-sensitization group and those in the insulin-provision group (P = 0.09). 7 Paradoxically, peripheral pitting oedema was more frequent in the former than in the latter group (P = 0.02). Notably, in this study, after 3 years of follow-up, 40% of the patients in the insulin-provision group had a HbA 1c < 7%. This finding is relevant as it indirectly suggests that exogenous insulin therapy may not be associated with an increased risk for HF if HbA 1c levels are at target. In the four RCTs considered in the meta-analysis of Cosmi et al., no information is provided about prior metabolic control, thus making problematic to speculate whether exogenous insulin treatment, independently of metabolic control, is linked to HF.
In the dispute whether insulin treatment is safe or not in patients with type 2 diabetes either without or with a history of HF, something is missing, i.e. an RCT primarily designed to test this endpoint. Furthermore, it will be clinically meaningful to determine whether insulin treatment may be more detrimental in patients with HF with preserved ejection fraction, a condition that is more associated with insulin resistance 8 than HF with reduced ejection fraction.
The availability of renal sodium-glucose co-transporter 2 (SGLT2) inhibitors and the results of the EMPA-REG OUTCOME trial and the Canagliflozin Cardiovascular Assessment Study (CAN-VAS) have fuelled enthusiasm in terms of HF treatment in patients with or without diabetes. However, it has been reported that more than 50% of HF patients have an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 and more than 10% have an eGFR <30 mL/min/1.73 m 2 : 9 in the former the glycaemic efficacy of SGLT2 would almost completely fade, in the latter the use of metformin and glucagon-like peptide-1 would not be allowed.
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Therefore, a consistent proportion of diabetic patients with HF is left with two therapeutic options, i.e. dipeptidyl peptidase-4 inhibitors and insulin. Thus, the claim that SGLT2 inhibitors are, by definition, the agents that antagonize the negative effects of insulin because they act independently of insulin, and antagonize the hormone's undesirable effects, can be acknowledged only in a relatively small proportion of HF patients.
Deriving information from meta-analysis of trials with unrelated endpoints or from real-world surveys will not unravel the dilemma whether insulin treatment is harmful for HF patients. 
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